TMUS
T-Mobile US, Inc.
TMUS's fundamentals are mixed, but it looks cheap: trading at 16x earnings, below its usual 27x. Analysts expect strong earnings growth.
VEON
VEON Ltd.
There isn't enough reported data to score VEON yet.
TMUS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Strong |
TMUS's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
VEON Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Healthy |
VEON's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
TMUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $171 | — |
| Current | 16x | $171 | — |
| Cheap | 21x | $218 | +27% |
| Fair | 26x | $274 | +60% |
| Expensive | 56x | $581 | +240% |
Historical ranges are pointers, not guarantees.
TMUS has the edge over VEON in the historical PE scenario, which offers more potential upside but is not a forecast.
VEON PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $63.62 | -15% |
| Fair | 8.5x | $83.40 | +11% |
| Current | 9.8x | $75.15 | — |
| Expensive | 10x | $103 | +37% |
Historical ranges are pointers, not guarantees.
VEON's PE is 9.8x, but its earnings don't support one, so it isn't a reliable read right now.
TMUS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for TMUS, with profitability improving.
VEON Forward outlook
There aren't enough analyst estimates for VEON to show an outlook.
TMUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.49 | +30% |
| Q3 2026 | $10.37 | -0.2% |
| Q2 2026 | $9.56 | -9.7% |
| Q1 2026 | $9.41 | -8.1% |
| Q4 2025 | $9.72 | +0.6% |
| Q3 2025 | $10.39 | +18% |
| Q2 2025 | $10.59 | +33% |
| Q1 2025 | $10.24 | +39% |
| Q4 2024 | $9.66 | +39% |
TMUS earned $10.37 per share over the past year, about the same as the year before.
VEON Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $9.82 | +409% |
| Q2 2025 | $10.07 | +$10.08 |
| Q1 2025 | $2.53 | -2.3% |
| Q4 2024 | $1.93 | -71% |
| Q4 2023 | $6.67 | +$8.92 |
| Q4 2022 | -$2.25 | -123% |
| Q4 2021 | $9.75 | +$14.73 |
| Q4 2020 | -$4.98 | -155% |
VEON has the edge over TMUS in the latest year-over-year earnings comparison.
TMUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $23.6B | +7.4% |
| Q2 2026 | $22.8B | +7.9% |
| Q1 2026 | $23.1B | +11% |
| Q4 2025 | $24.3B | +11% |
| Q3 2025 | $22B | +8.9% |
| Q2 2025 | $21.1B | +6.9% |
| Q1 2025 | $20.9B | +6.6% |
| Q4 2024 | $21.9B | +6.8% |
TMUS's revenue has grown year over year for 10 quarters in a row: $23.6B last quarter, up 7.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +3.4 points |
| Q2 2026 | 24% | -0.6 points |
| Q1 2026 | 19% | -3.5 points |
| Q4 2025 | 15% | -5.6 points |
| Q3 2025 | 21% | -3.2 points |
| Q2 2025 | 25% | +1.3 points |
| Q1 2025 | 23% | +2.6 points |
| Q4 2024 | 21% | +4 points |
TMUS's operating margin was 24% last quarter, up 3.4 points from the same quarter a year ago.
VEON Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $2.3B | +12% |
| Q2 2025 | $1.1B | +5.8% |
| Q1 2025 | $1B | +8.9% |
| Q4 2024 | $2B | +7.2% |
| Q2 2024 | $1B | +12% |
| Q1 2024 | $942M | +6.6% |
| Q4 2023 | $1.9B | -49% |
| Q4 2022 | $3.8B | -52% |
VEON has the edge over TMUS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 17% | -10 points |
| Q2 2025 | 75% | +54 points |
| Q1 2025 | 23% | -2.1 points |
| Q4 2024 | 31% | +4.6 points |
| Q2 2024 | 27% | +3.9 points |
| Q1 2024 | 21% | -9.6 points |
| Q4 2023 | 25% | +5.6 points |
| Q2 2023 | 26% | +29 points |
VEON's operating margin was 17% last quarter, down 10 points from the same quarter a year ago.
TMUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +5.3% |
| Q2 2026 | $4.8B | +4.4% |
| Q1 2026 | $4.6B | +4.6% |
| Q4 2025 | $4.2B | +25% |
| Q3 2025 | $4.8B | +15% |
| Q2 2025 | $4.6B | +32% |
| Q1 2025 | $4.4B | +79% |
| Q4 2024 | $3.3B | +2% |
TMUS generated $18.7B in free cash flow over the past year, up 8.8% from the year before.
VEON Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $408M | +3.6% |
| Q2 2025 | -$48M | -167% |
| Q1 2025 | $255M | +410% |
| Q4 2024 | $394M | -17% |
| Q2 2024 | $72M | -78% |
| Q1 2024 | $50M | -86% |
| Q4 2023 | $476M | +59% |
| Q4 2022 | $299M | -48% |
VEON still generates free cash flow, though less than at its 2016 peak: $1B over the past year.
TMUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -10.8M shares |
| 1 year | -4.9% | -55M shares |
| 3 years | -8.8% | -103M shares |
| 5 years | -15% | -182M shares |
| Available history | +24% | +207M shares |
TMUS has the edge over VEON on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.4B |
| Q2 2026 | $2.3B |
| Q1 2026 | $4.8B |
| Q4 2025 | $2.4B |
| Q3 2025 | $2.5B |
| Q2 2025 | $2.6B |
| Q1 2025 | $2.5B |
| Q4 2024 | $4.7B |
TMUS spent $12B buying back its own shares over the past year, down 1.7% from the year before.
VEON Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2459% | +1.7B shares |
| 1 year | +2439% | +1.7B shares |
| 3 years | +2488% | +1.7B shares |
| 5 years | +2464% | +1.7B shares |
| Available history | +2464% | +1.7B shares |
VEON has 1.8B diluted shares, up 2439% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $37M |
| Q2 2025 | $44M |
| Q1 2025 | $24M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q2 2020 | — |
TMUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.0x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | 2.4x | Moderate |
TMUS's net debt is less than a year of its operating earnings (EBITDA).
VEON Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 0.8x | Very low |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.6x | Healthy |
| Q4 2024 | 0.9x | Very low |
| Q2 2024 | 2.1x | Moderate |
| Q1 2024 | 2.0x | Moderate |
| Q4 2023 | 1.1x | Healthy |
| Q4 2022 | 1.8x | Healthy |
VEON's net debt is less than a year of its operating earnings (EBITDA), down from 2.0 years a year ago.
TMUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.9 | Neutral |
| Stochastic | 42.1 | Neutral |
TMUS's weekly RSI is 48 (neutral) and its Stochastic is 42 (neutral).
VEON Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.7 | Neutral |
| Stochastic | 70.6 | Neutral |
VEON's weekly RSI is 65 (neutral) and its Stochastic is 71 (neutral).
TMUS PE vs Communication Services Sector
| Metric | TMUS | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 16x | Same PE |
| PE % | 1 | 26 | 25 pts below |
TMUS is trading at 16x earnings, in line with the Communication Services sector's median of 16x.
VEON PE vs Communication Services Sector
| Metric | VEON | Sector median | Relative |
|---|---|---|---|
| PE | 9.8x | 16x | 41% below |
| PE % | 77 | 26 | 51 pts above |
VEON has the edge over TMUS on valuation relative to its sector.
TMUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $159.1 | 7.5% above |
| 20 week MA | $172.0 | 0.5% below |
| 50 week MA | $187.8 | 8.9% below |
| 100 week MA | $212.9 | 20% below |
| 200 week MA | $188.7 | 9.4% below |
TMUS has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 9.4% below its 200-week average.
VEON Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $78.4 | 4.2% below |
| 20 week MA | $66.1 | 14% above |
| 50 week MA | $57.9 | 30% above |
| 100 week MA | $52.9 | 42% above |
| 200 week MA | $37.7 | 100% above |
VEON has the edge over TMUS on trend strength, trading above more of its moving averages.
TMUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $77.2 | $132.9 | +72% |
| 2021 | $132.9 | $119.9 | -9.8% |
| 2022 | $119.9 | $140.0 | +17% |
| 2023 | $140.0 | $160.3 | +15% |
| 2024 | $160.3 | $223.0 | +39% |
| 2025 | $223.0 | $201.0 | -9.9% |
| 2026 YTD | $201.0 | $171.0 | -15% |
TMUS has finished higher in four of the last six years. It's down 15% so far in 2026.
VEON Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $63.3 | $40.3 | -36% |
| 2021 | $40.3 | $41.8 | +3.7% |
| 2022 | $41.8 | $11.5 | -72% |
| 2023 | $11.5 | $19.7 | +71% |
| 2024 | $19.7 | $39.0 | +98% |
| 2025 | $39.0 | $52.7 | +35% |
| 2026 YTD | $52.7 | $75.2 | +43% |
VEON has the edge over TMUS on returns for 2026, with the stronger performance.